

Godavari Biorefineries Ltd

Dated: December 5, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Symbol: GODAVARIB Script Code:544279

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that our United States based patent application, "COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH," from the Anti-Cancer Research Segment, has been granted.

This patent discloses novel chemical compounds, their synthesis process and biological activity, which inhibit unregulated cell growth by primarily targeting cancer stem cells. These compounds have demonstrated strong potential for treating various cancers, including breast and prostate cancer.

Grant Certificate is attached herewith for reference.

This is for your information and records.

Thanking you, Yours faithfully

For Godavari Biorefineries Limited Manoj Jain

Company Secretary and Compliance Officer Membership No. F-7998









The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, Shis United States

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 u.s.c. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 u.s.c. 41(b). See the Maintenance Fee Notice on the inside of the cover.

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



(12) United States Patent

Gavade et al.

US 12,459,930 B2 (10) **Patent No.:**

(45) Date of Patent:

*Nov. 4, 2025

(54) COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH

(71) Applicant: GODAVARI BIOREFINERIES

LIMITED, Maharashtra (IN)

(72) Inventors: **Sandip Gavade**, Maharashtra (IN);

Maithili Athavale, Maharashtra (IN); Sangeeta Srivastava, Maharashtra (IN); Prashant Kharkar, Maharashtra (IN)

Assignee: **GODAVARI BIOREFINERIES**

LIMITED, Maharashtra (IN)

Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 941 days.

This patent is subject to a terminal dis-

claimer.

17/415,676 (21) Appl. No.:

(22) PCT Filed: Dec. 16, 2019

(86) PCT No.: PCT/IN2019/050926

§ 371 (c)(1),

(2) Date: Jun. 17, 2021

(87) PCT Pub. No.: WO2020/129082

PCT Pub. Date: Jun. 25, 2020

(65)**Prior Publication Data**

> US 2022/0073501 A1 Mar. 10, 2022

(30)Foreign Application Priority Data

Dec. 17, 2018 (IN) 201821047582

(51) Int. Cl. C07D 407/04 (2006.01)A61P 35/00 (2006.01)

(Continued)

(52) U.S. Cl.

CPC C07D 407/04 (2013.01); A61P 35/00

(2018.01); *C07D* 295/088 (2013.01);

(Continued)

(58) Field of Classification Search

CPC ... A61P 35/00; C07D 407/04; C07D 295/088;

C07D 317/54; C07D 405/04; C07D

493/04

See application file for complete search history.

(56)References Cited

FOREIGN PATENT DOCUMENTS

103467463 A CN WO 12/2013

WO 2013001352 A2 1/2013

(Continued)

OTHER PUBLICATIONS

Berge et al. Pharmaceutical salts. J Pharm Sci. 1977;66(1):1-19.

(Year: 1977).*

(Continued)

Primary Examiner — Joseph K Mckane

Assistant Examiner - Ashli Ariana Chicks

(74) Attorney, Agent, or Firm — Intellectual Property

Law Group LLP

(57)**ABSTRACT**

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.

21 Claims, 35 Drawing Sheets

